ADA adds updates to 2018 Standards of Medical Care in Diabetes
The ADA has revised the definition of hypoglycemia in Section 6 - Glycemic Targets and Section 14 - Diabetes Care in the Hospital of the 2018 Standards of Care to align with the three levels of hypoglycemia as defined in the Consensus Report published in December 2017. Two new FDA-approved drugs - the GLP-1 receptor agonist semaglutide and the SGLT2 inhibitor ertugliflozin as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes - have been added to Section
To continue reading this article
Continue reading your article with a eMediNexus account.